Johnson & Johnson vs. Seres Therapeutics, Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| JNJ | MCRB | |
|---|---|---|
| Market Cap | $624.74 billion | $48.41 million |
| Revenue (TTM) | $97.93 billion | $1.88 million |
| Net Income (TTM) | $21.04 billion | $-22,463,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | MCRB | |
|---|---|---|
| P/E Ratio | 30.07 | — |
| Price / Book | 7.35 | 1.40 |
| Price / Sales | 6.38 | 25.71 |
JNJ and MCRB split the valuation factors evenly.
Profitability
| JNJ | MCRB | |
|---|---|---|
| Net Margin | 21.48% | -1192.94% |
| Return on Equity | 24.76% | -65.05% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | MCRB | |
|---|---|---|
| Dividend Yield | 2.07% | — |
| Payout Ratio | 62.18 | — |
JNJ and MCRB split the dividend factors evenly.
Risk & Sentiment
| JNJ | MCRB | |
|---|---|---|
| Short Interest | 0.67% | 49.60% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, MCRB overview, MCRB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.